# Sickle Cell Disease FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/sickle-cell-disease

> 11 upcoming FDA catalysts in sickle Cell Disease: PCV21 (SNY) on Jan to Apr 2027 (topline data readout); PCV21 (SNY) on January 2027 (primary completion); AQVESME™ (mitapivat, AGIO) on February 1, 2027 (PDUFA date); Wayrilz (rilzabrutinib, SNY) on Jul to Oct 2027 (topline data readout); and 7 more.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, quarter only, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| July 24, 2025 | [Ndec - oral decitabine-tetrahydrouridine primary completion](https://sec-api.dev/pdufa/ndec-oral-decitabine-tetrahydrouridine) | NVO | Sickle Cell Disease | completed | "NCT05405114 (Research Study Investigating How Well NDec Works in People With Sickle Cell Disease): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-07-24 (ACTUAL); Lead Sponsor Novo Nordisk A/S." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05405114)) |
| October 30, 2025 | [AQVESME™ (mitapivat) primary completion](https://sec-api.dev/pdufa/mitapivat) | AGIO | Sickle Cell Disease | completed | "NCT05031780 (A Study Evaluating the Efficacy and Safety of Mitapivat (AG-348) in Participants With Sickle Cell Disease (RISE UP)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2025-10-30 (ACTUAL); Lead Sponsor Agios Pharmaceuticals, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05031780)) |
| March 9, 2026 | [Etavopivat primary completion](https://sec-api.dev/pdufa/etavopivat) | NVO | Sickle Cell Disease | completed | "NCT05725902 (Study of the Effect of Etavopivat on Cerebral Hemodynamic Response in Children With Sickle Cell Disease): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2026-03-09 (ACTUAL); Lead Sponsor Novo Nordisk A/S." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05725902)) |
| May 12, 2026 | [Tebapivat primary completion](https://sec-api.dev/pdufa/tebapivat) | AGIO | Sickle Cell Disease | completed | "NCT06924970 (A Dose-Finding Study of Tebapivat to Assess Efficacy, and Safety in Participants With Sickle Cell Disease (SCD)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-05-12 (ACTUAL); Lead Sponsor Agios Pharmaceuticals, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06924970)) |
| June 4, 2026 | [Pociredir primary completion](https://sec-api.dev/pdufa/pociredir) | FULC | Sickle Cell Disease | withdrawn | "NCT07401823 (Open-Label Extension Study to Pioneer Study 6058-SCD-101): Overall Status TERMINATED; Phase PHASE2; Primary Completion 2026-06-04 (ACTUAL); Lead Sponsor Fulcrum Therapeutics." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07401823)) |
| Jan to Apr 2027 | [PCV21 topline data readout](https://sec-api.dev/pdufa/pcv21) | SNY | Sickle Cell Disease | scheduled | "NCT07247188 (Study of a Single Dose of a 21-valent Pneumococcal Conjugate Vaccine in Children and Adolescents With Sickle Cell Disease): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-01-07 (ESTIMATED); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07247188)) |
| January 2027 | [PCV21 primary completion](https://sec-api.dev/pdufa/pcv21) | SNY | Sickle Cell Disease | scheduled | "NCT07247188 (Study of a Single Dose of a 21-valent Pneumococcal Conjugate Vaccine in Children and Adolescents With Sickle Cell Disease): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-01-07 (ESTIMATED); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07247188)) |
| February 1, 2027 | [AQVESME™ (mitapivat) PDUFA date](https://sec-api.dev/pdufa/mitapivat) | AGIO | sickle cell disease | scheduled | "•New PDUFA goal date for mitapivat sickle cell disease sNDA set for February 1, 2027; company is launch-ready and in labeling discussions with FDA" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1439222/000143922226000129/agio-110526xfyxex991earnin.htm)) |
| Jul to Oct 2027 | [Wayrilz (rilzabrutinib) topline data readout](https://sec-api.dev/pdufa/rilzabrutinib) | SNY | Sickle Cell Disease | scheduled | "NCT06975865 (The Efficacy and Safety of Rilzabrutinib in Participants Aged 10 to 65 Years With Sickle-cell Disease): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-07-23 (ESTIMATED); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06975865)) |
| July 2027 | [Wayrilz (rilzabrutinib) primary completion](https://sec-api.dev/pdufa/rilzabrutinib) | SNY | Sickle Cell Disease | scheduled | "NCT06975865 (The Efficacy and Safety of Rilzabrutinib in Participants Aged 10 to 65 Years With Sickle-cell Disease): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-07-23 (ESTIMATED); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06975865)) |
| Aug to Nov 2027 | [Etavopivat topline data readout](https://sec-api.dev/pdufa/etavopivat) | NVO | Sickle Cell Disease | scheduled | "NCT06612268 (A Study to Evaluate How Well Etavopivat Works in People With Sickle Cell Disease): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-08-27 (ESTIMATED); Lead Sponsor Novo Nordisk A/S." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06612268)) |
| August 2027 | [Etavopivat primary completion](https://sec-api.dev/pdufa/etavopivat) | NVO | Sickle Cell Disease | scheduled | "NCT06612268 (A Study to Evaluate How Well Etavopivat Works in People With Sickle Cell Disease): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-08-27 (ESTIMATED); Lead Sponsor Novo Nordisk A/S." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06612268)) |
| Jul to Oct 2029 | [Crizanlizumab topline data readout](https://sec-api.dev/pdufa/crizanlizumab) | NVS | Sickle Cell Disease | scheduled | "NCT06439082 (A Study to Investigate the Efficacy and Safety of Crizanlizumab (5 mg/kg) Compared With Placebo in Adolescent and Adult Sickle Cell Disease Patients Who Experience Frequent Vaso-Occlusive Crises (SPARKLE)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-07-02 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06439082)) |
| July 2029 | [Crizanlizumab primary completion](https://sec-api.dev/pdufa/crizanlizumab) | NVS | Sickle Cell Disease | scheduled | "NCT06439082 (A Study to Investigate the Efficacy and Safety of Crizanlizumab (5 mg/kg) Compared With Placebo in Adolescent and Adult Sickle Cell Disease Patients Who Experience Frequent Vaso-Occlusive Crises (SPARKLE)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-07-02 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06439082)) |
| August 2029 | [AQVESME™ (mitapivat) primary completion](https://sec-api.dev/pdufa/mitapivat) | AGIO | Sickle Cell Disease | scheduled | "NCT07656415 (A Study to Investigate the Effect of Mitapivat on Transfusion Burden in Subjects With Sickle Cell Disease (SCD)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-08 (ESTIMATED); Lead Sponsor Agios Pharmaceuticals, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07656415)) |
| Aug to Nov 2029 | [AQVESME™ (mitapivat) topline data readout](https://sec-api.dev/pdufa/mitapivat) | AGIO | Sickle Cell Disease | scheduled | "NCT07656415 (A Study to Investigate the Effect of Mitapivat on Transfusion Burden in Subjects With Sickle Cell Disease (SCD)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-08 (ESTIMATED); Lead Sponsor Agios Pharmaceuticals, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07656415)) |

## Drugs

- [Ndec - oral decitabine-tetrahydrouridine](https://sec-api.dev/pdufa/ndec-oral-decitabine-tetrahydrouridine) (NVO)
- [AQVESME™ (mitapivat)](https://sec-api.dev/pdufa/mitapivat) (AGIO)
- [Etavopivat](https://sec-api.dev/pdufa/etavopivat) (NVO)
- [Tebapivat](https://sec-api.dev/pdufa/tebapivat) (AGIO)
- [Pociredir](https://sec-api.dev/pdufa/pociredir) (FULC)
- [PCV21](https://sec-api.dev/pdufa/pcv21) (SNY)
- [Wayrilz (rilzabrutinib)](https://sec-api.dev/pdufa/rilzabrutinib) (SNY)
- [Crizanlizumab](https://sec-api.dev/pdufa/crizanlizumab) (NVS)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/sickle-cell-disease.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Sickle Cell Disease FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/sickle-cell-disease

```bibtex
@misc{secapidev_indications_sickle_cell_disease_20261116,
  title        = {Sickle Cell Disease FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/sickle-cell-disease}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_sickle_cell_disease_20261116","title":"Sickle Cell Disease FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/sickle-cell-disease","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
